MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.59 (−46.03%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MYRIAD GENETICS INC saw revenue fall 3.2% to $806.60M over the twelve months to Jun 30, 2026.
Revenue
$806.60M
-3.2% vs. a year earlier
Operating income
-$98.60M
TTM Q2 2026
EPS, diluted
-$1.19
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $399.11M
- P/E ratio
- –
- Price to sales
- 0.49
- Price to book
- 1.31
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $806.60M
- Net income
- -$112.60M
- EPS, diluted
- -$1.19
- Book value per share
- $3.21
- Diluted shares
- 95M
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
$806.60M-3.2% YoY
Gross profit
$555.20M-5.4% YoY
Operating income
-$98.60M
Net income
-$112.60M
EPS, diluted
-$1.19
Free cash flow
–
Reported periodTrailing twelve months